Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CRD137
MIFTS: 45

Cardiogenic Shock

Categories: Rare diseases, Cardiovascular diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Cardiogenic Shock

About this section

MalaCards integrated aliases for Cardiogenic Shock:

Name: Cardiogenic Shock 59 63
Shock, Cardiogenic 73
Shock Cardiogenic 55

Characteristics:

Orphanet epidemiological data:

59
cardiogenic shock
Prevalence: 1-5/10000 (Europe);

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Cardiovascular diseases
See all MalaCards categories (disease lists)
ICD10: 34 33


External Ids:

Orphanet 59 ORPHA97292
UMLS via Orphanet 74 C0036980
ICD10 via Orphanet 34 R57.0
ICD10 33 R57.0
UMLS 73 C0036980
Sources

Summaries for Cardiogenic Shock

About this section
PubMed Health : 63 About cardiogenic shock: Cardiogenic (kar-dee-oh-JE-nik) shock is a condition in which a suddenly weakened heart isn't able to pump enough blood to meet the body's needs. The condition is a medical emergency and is fatal if not treated right away.The most common cause of cardiogenic shock is damage to the heart muscle from a severe heart attack. However, not everyone who has a heart attack has cardiogenic shock. In fact, on average, only about 7 percent of people who have heart attacks develop the condition.If cardiogenic shock does occur, it's very dangerous. When people die from heart attacks in hospitals, cardiogenic shock is the most common cause of death.

MalaCards based summary : Cardiogenic Shock, also known as shock, cardiogenic, is related to myocarditis and atrioventricular block, and has symptoms including syncope and shock without mention of trauma. An important gene associated with Cardiogenic Shock is NPPB (Natriuretic Peptide B), and among its related pathways/superpathways are Folate Metabolism and IL6-mediated signaling events. The drugs Lidocaine and Clopidogrel have been mentioned in the context of this disorder. Affiliated tissues include heart, liver and kidney.

Wikipedia : 76 Cardiogenic shock is a medical emergency resulting from inadequate blood flow due to the dysfunction of... more...

Sources

Related Diseases for Cardiogenic Shock

About this section

Diseases related to Cardiogenic Shock via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 209)
# Related Disease Score Top Affiliating Genes
1 myocarditis 30.6 IL6 NPPB
2 atrioventricular block 30.5 NPPB PIK3C2A
3 infective endocarditis 29.8 CRP IL6
4 peripheral artery disease 29.8 CRP IL6
5 takayasu arteritis 29.7 CRP IL6
6 myocardial infarction 29.5 CRP IL6 NPPB PIK3C2A PLAT
7 inferior myocardial infarction 29.3 NPPB PIK3C2A PLAT
8 pneumonia 29.2 CRP IL6 PIK3C2A
9 acute myocardial infarction 29.1 CRP NPPB PIK3C2A PLAT
10 pericarditis 29.1 CRP IL6 NPPB
11 pulmonary edema 29.1 CRP NPPB PIK3C2A
12 kawasaki disease 29.1 CRP IL6 NPPB
13 wegener granulomatosis 28.9 CRP IL6
14 pulmonary embolism 28.8 CRP NPPB PLAT
15 pulmonary hypertension 28.7 IL6 NPPB PLAT
16 arteries, anomalies of 28.2 CRP IL6 NPPB PLAT
17 endocarditis 28.0 CRP IL6 PIK3C2A PLAT
18 coronary artery anomaly 27.2 CRP IL6 NPPB PIK3C2A PLAT
19 cardiac tamponade 11.4
20 ogden syndrome 11.1
21 hypoplastic left heart syndrome 11.1
22 ischemia 10.4
23 toxic myocarditis 10.4 NPPB PIK3C2A
24 hand, foot and mouth disease 10.4 IL6 NPPB
25 vibrio vulnificus infection 10.3 IL6 PIK3C2A
26 cardiac arrest 10.3
27 crimean-congo hemorrhagic fever 10.3 IL6 PIK3C2A
28 chronic thromboembolic pulmonary hypertension 10.3 CRP NPPB
29 thrombosis 10.3
30 extrinsic cardiomyopathy 10.3 IL6 PIK3C2A
31 pheochromocytoma 10.2
32 cold agglutinin disease 10.2 CRP IL6
33 cryopyrin-associated periodic syndrome 10.2 CRP IL6
34 acute cholangitis 10.2 CRP IL6
35 neutrophilia, hereditary 10.2 CRP IL6
36 uremic pruritus 10.2 CRP IL6
37 spinal disease 10.2 CRP IL6
38 castleman disease 10.2 CRP IL6
39 heart conduction disease 10.2 CRP NPPB
40 angina pectoris 10.2 CRP IL6
41 viral pneumonia 10.2 CRP IL6
42 cecal disease 10.2 CRP IL6
43 relapsing polychondritis 10.2 CRP IL6
44 central nervous system vasculitis 10.2 CRP IL6
45 subacute thyroiditis 10.2 CRP IL6
46 intussusception 10.2 CRP IL6
47 louse-borne relapsing fever 10.2 CRP IL6
48 multicentric castleman disease 10.2 CRP IL6
49 hypersensitivity reaction type iii disease 10.2 CRP IL6
50 aortic valve disease 1 10.2 CRP NPPB

Comorbidity relations with Cardiogenic Shock via Phenotypic Disease Network (PDN): (show all 19)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Aortic Valve Disease 1
Cardiac Arrest Chronic Kidney Failure
Chronic Myocardial Ischemia Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Intermediate Coronary Syndrome Ischemic Heart Disease
Kidney Disease Mitral Valve Disease
Peripheral Vascular Disease Respiratory Failure
Third-Degree Atrioventricular Block Tricuspid Valve Disease
Ventricular Fibrillation, Paroxysmal Familial, 1

Graphical network of the top 20 diseases related to Cardiogenic Shock:



Diseases related to Cardiogenic Shock
Sources

Symptoms & Phenotypes for Cardiogenic Shock

About this section

UMLS symptoms related to Cardiogenic Shock:


syncope, shock without mention of trauma
Sources

Drugs & Therapeutics for Cardiogenic Shock

About this section

PubMedHealth treatment related to Cardiogenic Shock: 63

Cardiogenic shock is life threatening and requires emergency medical treatment. The condition usually is diagnosed after a person has been admitted to a hospital for a heart attack. If the person isn't already in a hospital, emergency treatment can start as soon as medical personnel arrive.The first goal of emergency treatment for cardiogenic shock is to improve the flow of blood and oxygen to the body’s organs.Sometimes both the shock and its cause are treated at the same time. For example, doctors may quickly open a blocked blood vessel that's damaging the heart. Often, this can get the patient out of shock with little or no additional treatment.

Drugs for Cardiogenic Shock (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 200)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4,Phase 1 137-58-6 3676
2
Clopidogrel Approved Phase 4,Phase 2,Phase 3,Not Applicable 120202-66-6, 113665-84-2 60606
3
Dobutamine Approved Phase 4,Phase 3,Phase 2 34368-04-2 36811
4
Dexmedetomidine Approved, Vet_approved Phase 4,Not Applicable 113775-47-6 68602 5311068
5
Ticagrelor Approved Phase 4 274693-27-5 9871419
6
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 9005-49-6 772 46507594
7
Norepinephrine Approved Phase 4,Phase 3 51-41-2 439260
8
Abciximab Approved Phase 4,Phase 3 143653-53-6
9
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2 22916-47-8 4189
10
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
11
Everolimus Approved Phase 4 159351-69-6 6442177
12
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
13
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
14
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
15
Tenecteplase Approved Phase 4,Phase 2,Phase 3 191588-94-0
16
Racepinephrine Approved Phase 4,Phase 2 329-65-7 838
17
Furosemide Approved, Vet_approved Phase 4,Phase 3 54-31-9 3440
18
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-78-2 2244
19
Milrinone Approved Phase 4 78415-72-2 4197
20
Apixaban Approved Phase 4,Phase 3 503612-47-3 10182969
21
Rivaroxaban Approved Phase 4,Phase 3 366789-02-8
22
Ticlopidine Approved Phase 4 55142-85-3 5472
23
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
24
Chromium Approved Phase 4 7440-47-3 27668
25
Serine Approved, Nutraceutical Phase 4,Phase 3 56-45-1 5951
26 Simendan Investigational Phase 4,Phase 2,Phase 3 131741-08-7
27 Analgesics Phase 4,Phase 3,Not Applicable
28 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Central Nervous System Depressants Phase 4,Phase 2,Phase 1,Not Applicable
30 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Not Applicable
32 Adrenergic alpha-2 Receptor Agonists Phase 4,Not Applicable
33 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Not Applicable
34 Adrenergic beta-Agonists Phase 4,Phase 3,Phase 2
35 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Analgesics, Non-Narcotic Phase 4,Phase 3,Not Applicable
37 Cytochrome P-450 Enzyme Inhibitors Phase 4
38 Anesthetics Phase 4,Phase 1,Not Applicable
39 Anesthetics, Local Phase 4,Phase 1
40 Anti-Arrhythmia Agents Phase 4,Phase 2,Phase 3,Phase 1
41 Vasodilator Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
42 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Anti-Bacterial Agents Phase 4,Not Applicable
45 Hypnotics and Sedatives Phase 4,Not Applicable
46 Phosphodiesterase Inhibitors Phase 4,Phase 2,Phase 3
47 Antihypertensive Agents Phase 4,Phase 1,Not Applicable
48 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2
49 Anticoagulants Phase 4,Phase 3,Phase 2,Not Applicable
50 Anti-Infective Agents Phase 4,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 173)
# Name Status NCT ID Phase Drugs
1 Thrombus Aspiration in Patients With STEMI Unknown status NCT02606435 Phase 4
2 Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock Completed NCT01367743 Phase 4 epinephrine perfusion;norepinephrine perfusion
3 Culprit Lesion Only PCI Versus Multivessel PCI in Cardiogenic Shock Completed NCT01927549 Phase 4
4 Intraaortic Balloon Pump in Cardiogenic Shock II Completed NCT00491036 Phase 4
5 Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock Completed NCT00420030 Phase 4 Abciximab
6 Efficacy Study of LV Assist Device to Treat Patients With Cardiogenic Shock (ISAR-SHOCK) Completed NCT00417378 Phase 4
7 Acute Chest Pain Treatment and Evaluation (ACTION) Study Completed NCT00434564 Phase 4
8 Levosimendan in Acute Heart Failure Following Acute Myocardial Infarction. Completed NCT00324766 Phase 4 levosimendan;placebo,
9 Addition of Dexmedetomidine to Ropivacaine-induced Supraclavicular Block (ADRIB Trial) Completed NCT02630290 Phase 4 Ropivacaine;Ropivacaine + Dexmedetomidine
10 Safety and Efficacy Study Comparing 3 New Types of Coronary Stents Completed NCT01166685 Phase 4
11 To Investigate the Role of Upstream High Dose Statin in STEMI Completed NCT01050348 Phase 4 Atorvastatin calcium;Inactive Placebo
12 Providing Rapid Out of Hospital Acute Cardiovascular Treatment (PROACT) Completed NCT01634425 Phase 4
13 Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion. The METOCARD-CNIC Trial. Completed NCT01311700 Phase 4 Injectable (i.v.) metoprolol tartrate (up to 15 mg).
14 Effect of Ivabradine in Stage D HF/Cardiogenic Shock Patients on Dobutamine Recruiting NCT03387605 Phase 4 Ivabradine;Placebo
15 Milrinone Versus Dobutamine in Critically Ill Patients Recruiting NCT03207165 Phase 4 Milrinone;Dobutamine
16 Diuretic Vascular Filling in the Initial Management of Acute PE With Right Ventricular Dysfunction Normotensive Recruiting NCT02531581 Phase 4 Furosemide;NaCl 9% isotonic
17 Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation Recruiting NCT02666157 Phase 4 Dabigatran etexilate;Rivaroxaban;Apixaban
18 Clinical Study of Extra-Corporal Life Support in Cardiogenic Shock Complicating Acute Myocardial Infarction Active, not recruiting NCT02544594 Phase 4
19 PROMUS Element Plus US Post-Approval Study Active, not recruiting NCT01589978 Phase 4 Aspirin;P2Y12 antagonist
20 Efficacy and Safety on Heart Rate Control With Ivabradine on Cardiogenic Shock Not yet recruiting NCT03437369 Phase 4 Ivabradine Oral Tablet
21 Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction Not yet recruiting NCT03551964 Phase 4 Cangrelor;Ticagrelor
22 Evaluation of Early CRRT and Beta-blocker InTerventions in Patients With ECMO(ELITE) Not yet recruiting NCT03549923 Phase 4 Esmolol;Standard care
23 Comparison of Standard Treatment Versus Standard Treatment Plus Extracorporeal Life Support (ECLS) in Myocardial Infarction Complicated With Cardiogenic Shock Terminated NCT00314847 Phase 4
24 A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI) Terminated NCT00168792 Phase 4 Tenecteplase
25 Danish Cardiogenic Shock Trial Unknown status NCT01633502 Phase 3
26 Anti-inflammatory Effect of Therapeutic Hypothermia in Acute Myocardial Infarction Complicated With Cardiogenic Shock Unknown status NCT02633358 Phase 2, Phase 3
27 Liberal Versus Restrictive Use of Dobutamine in Cardiac Surgery Unknown status NCT02361801 Phase 3 Liberal dobutamine protocol;Restrictive dobutamine protocol
28 Adjunctive Mild Hypothermia Therapy to Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Complicated With Shock: A Feasibility Study Unknown status NCT00846222 Phase 3
29 Levosimendan Versus Dobutamine in Shock Patients Unknown status NCT00093301 Phase 2, Phase 3 Levosimendan;Dobutamine
30 Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients Unknown status NCT02432976 Phase 2, Phase 3 Exenatide;Insulin
31 Impact of Different Treatment in Multivessel Non ST Elevation Myocardial Infarction (NSTEMI) Patients: One Stage Versus Multistaged Percutaneous Coronary Intervention (PCI) Unknown status NCT01478984 Phase 3
32 Best Bypass Surgery (BBS) Trial Unknown status NCT00120991 Phase 3
33 Shock Trial: Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. Completed NCT00000552 Phase 3 thrombolytic therapy
34 A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse) Completed NCT00046228 Phase 3 abciximab placebo; reteplase placebo, abciximab, abciximab;Abciximab; reteplase; abciximab placebo; abciximab;abciximab; reteplase placebo; abciximab placebo; abciximab;abciximab placebo; reteplase placebo, abciximab, abciximab;abciximab; reteplase placebo; abciximab placebo; abciximab;Abciximab; reteplase; abciximab placebo; abciximab
35 Safety and Efficacy Study of Eptifibatide in Primary Percutaneous Coronary Intervention (PCI) Completed NCT00251823 Phase 3 Eptifibatide facilitated PCI
36 The STREAM Percutaneous Coronary Intervention Anticoagulant Sub-study Completed NCT00882635 Phase 3 enoxaparin;Unfractionated heparin
37 Dopamine and Norepinephrine in Shock Patients Completed NCT00314704 Phase 3 dopamine versus norepinephrine
38 Which Therapy for Acute Heart Attacks? (The WEST Study) Completed NCT00121446 Phase 2, Phase 3 tenecteplase;enoxaparin;clopidogrel
39 STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction Completed NCT00623623 Phase 3 enoxaparin;tenecteplase;clopidogrel
40 REsearching Coronary REduction by Appropriately Targeting Euglycemia (RECREATE Pilot Study) Completed NCT00640991 Phase 3 glulisine insulin, glargine insulin
41 Exenatide for Stress Hyperglycemia Completed NCT01969149 Phase 2, Phase 3 Exenatide;Insulin
42 An Efficacy and Outcome Study of Supplemental Oxygen Treatment in Patients With Suspected Myocardial Infarction Completed NCT01787110 Phase 3 Oxygen
43 Minimal Invasive Procedure for Myocardial Infarction Completed NCT01360242 Phase 3
44 Bromocriptine in the Treatment of Peripartum Cardiomyopathy Recruiting NCT02590601 Phase 3 Bromocriptine
45 Performance of Bioresorbable Scaffold in Primary Percutaneous Intervention of ST Elevation Myocardial Infarct Active, not recruiting NCT02067091 Phase 3
46 Norepinephrine vs Norepinephrine and Dobutamine in Cardiogenic Shock Not yet recruiting NCT03340779 Phase 3 Norepinephrine
47 Vasopressin or Norepinephrine in Vasoplegic Shock After Non-cardiac Surgery Not yet recruiting NCT03483753 Phase 2, Phase 3 Vasopressin;Norepinephrine
48 Effect of External Counter Pulsation on Ischemic Stroke Not yet recruiting NCT03075137 Phase 3
49 Efficacy of Furosemide Versus Vascular Filling in Patients With Acute Myocardial Infarction Not yet recruiting NCT02905760 Phase 3 Furosemide;Placebo filling;Placebo furosemide;Vascular filling
50 INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority Not yet recruiting NCT02832544 Phase 3 Rivaroxaban (20 mg);Vitamin K antagonists (VKA)

Search NIH Clinical Center for Cardiogenic Shock

Inferred drug relations via UMLS 73 / NDF-RT 51 :
Sources

Genetic Tests for Cardiogenic Shock

About this section
Sources

Anatomical Context for Cardiogenic Shock

About this section

MalaCards organs/tissues related to Cardiogenic Shock:

41
Heart, Liver, Kidney, Lung, Bone, Skeletal Muscle, Endothelial
Sources

Publications for Cardiogenic Shock

About this section

Articles related to Cardiogenic Shock:

(show top 50) (show all 750)
# Title Authors Year
1
MicroRNAs in pathophysiology of acute myocardial infarction and cardiogenic shock. ( 29947233 )
2018
2
Optimal course of treatment in acute cardiogenic shock complicating myocardial infarction. ( 29310471 )
2018
3
National Trends, Predictors of Use, and In-Hospital Outcomes in the Mechanical Circulatory Support for Cardiogenic Shock. ( 29400657 )
2018
4
Cardiogenic shock complicating peripartum cardiomyopathy: Importance of early left ventricular unloading and bromocriptine therapy. ( 29792513 )
2018
5
Acute heart failure following myocardial infarction: complement activation correlates with the severity of heart failure in patients developing cardiogenic shock. ( 29424484 )
2018
6
Norepinephrine as a First-Line Inopressor in Cardiogenic Shock: Oversimplification or Best Practice? ( 29976292 )
2018
7
The Use of ECMO for the Treatment of Refractory Cardiac Arrest or Postarrest Cardiogenic Shock Following In-Hospital Cardiac Arrest: A 10-Year Experience. ( 29303029 )
2018
8
Hospital mortality and thirty day readmission among patients with non-acute myocardial infarction related cardiogenic shock. ( 29929933 )
2018
9
A Targeted Management Approach to Cardiogenic Shock. ( 29907274 )
2018
10
Revascularization strategies in cardiogenic shock complicating acute myocardial infarction: A systematic review and meta-analysis. ( 29909948 )
2018
11
Outcome after revascularisation of acute myocardial infarction with cardiogenic shock on extracorporeal life support. ( 29400656 )
2018
12
Three-Dimensional Inferior Vena Cava for Assessing Central Venous Pressure in Patients with Cardiogenic Shock. ( 29908724 )
2018
13
Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. ( 29376560 )
2018
14
Cardiogenic Shock: A Rare Complication of Influenza. ( 29963343 )
2018
15
Implementation of a Cardiogenic Shock Team and Clinical Outcomes (INOVA-SHOCK Registry): Observational and Retrospective Study. ( 29954728 )
2018
16
A Right Insight in Cardiogenic Shock to Get It Right. ( 29374583 )
2018
17
Cardiogenic Shock: An Unusual Initial Presentation of Churg-Strauss Syndrome. ( 29808153 )
2018
18
Adenosine Plasma Level and A2A Receptor Expression in Patients With Cardiogenic Shock. ( 29923934 )
2018
19
Re. Multivessel Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction with Cardiogenic Shock. ( 29958193 )
2018
20
Comparison of temporary ventricular assist devices and extracorporeal life support in post-cardiotomy cardiogenic shock. ( 29905854 )
2018
21
Mortality in patients with cardiogenic shock treated with the Impella CP microaxial pump for isolated left ventricular failure. ( 29405734 )
2018
22
Tako-tsubo Cardiomyopathy Complicated With Cardiac Tamponade and Cardiogenic Shock. ( 29844005 )
2018
23
Vascular complications in adult postcardiotomy cardiogenic shock patients receiving venoarterial extracorporeal membrane oxygenation. ( 29916091 )
2018
24
Is index procedure complete revascularization really essential for ST-elevation myocardial infarction with cardiogenic shock? ( 29430782 )
2018
25
Veno-arterial extracorporeal membrane oxygenation as a bridge for enabling surgery in a patient under cardiogenic shock due to acute mitral prosthesis dysfunction. ( 29910584 )
2018
26
ECMO use and mortality in adult patients with cardiogenic shock: a retrospective observational study in U.S. hospitals. ( 29973150 )
2018
27
Blood lactate is a predictor of short-term mortality in patients with myocardial infarction complicated by heart failure but without cardiogenic shock. ( 29347907 )
2018
28
Plasma Concentration of Biomarkers Reflecting Endothelial Cell- and Glycocalyx Damage are Increased in Patients with Suspected St-Elevation Myocardial Infarction Complicated by Cardiogenic Shock. ( 29438221 )
2018
29
Reply: Revascularization Strategies in Patients With Acute MI and Cardiogenic Shock. ( 29929627 )
2018
30
Mechanical support in cardiogenic shock complicating acute coronary syndrome: ready for prime time? ( 29345584 )
2018
31
Cardiogenic shock: the next frontier in acute cardiovascular care! ( 29412021 )
2018
32
Assessment of Safety and Effectiveness of the Extracorporeal Continuous-Flow Ventricular Assist Device (BR16010) Use as a Bridge-to-Decision Therapy for Severe Heart Failure or Refractory Cardiogenic Shock: Study Protocol for Single-Arm Non-randomized, Uncontrolled, and Investigator-Initiated Clinical Trial. ( 29948739 )
2018
33
Revascularization Strategies in Patients With Acute MI and Cardiogenic Shock. ( 29929626 )
2018
34
Revision: prognostic impact of baseline glucose levels in acute myocardial infarction complicated by cardiogenic shock-a substudy of the IABP-SHOCK II-trial. ( 29423774 )
2018
35
Predictive Value of Procalcitonin for Infection and Survival in Adult Cardiogenic Shock Patients Treated with Extracorporeal Membrane Oxygenation. ( 29399566 )
2018
36
'Combat' Approach to Cardiogenic Shock. ( 29928313 )
2018
37
Extracorporeal life support in cardiogenic shock: indications and management in current practice. ( 29349674 )
2018
38
Epinephrine Versus Norepinephrine forA Cardiogenic Shock After AcuteA Myocardial Infarction. ( 29976291 )
2018
39
Cardiogenic shock and tako-tsubo cardiomyopathy in a 9-year-old girl with retroperitoneal paraganglioma. ( 29903891 )
2018
40
Regarding "Incidence and risk factors of groin lymphocele formation after venoarterial extracorporeal membrane oxygenation in cardiogenic shock patients". ( 29579476 )
2018
41
Early Electroencephalography Findings in Cardiogenic Shock Patients Treated by Venoarterial Extracorporeal Membrane Oxygenation. ( 29389771 )
2018
42
Weaning adult patients with cardiogenic shock on veno-arterial extracorporeal membrane oxygenation by pump-controlled retrograde trial off. ( 29409389 )
2018
43
Predictors of cardiogenic shock in cardiac surgery patients receiving intra-aortic balloon pumps. ( 29395233 )
2018
44
Use of noninvasive and invasive mechanical ventilation in cardiogenic shock: A prospective multicenter study. ( 28043661 )
2017
45
Early Initiation of Impella in Acute Myocardial Infarction Complicated byA Cardiogenic Shock Improves Survival: A Meta-Analysis. ( 28882288 )
2017
46
Levosimendan as a treatment for acute renal failure associated with cardiogenic shock after hip fracture. ( 28017176 )
2017
47
Temporary Biventricular Assist Device to Bridge a Patient With Cardiogenic Shock Due to AL Amyloidosis to Heart Transplantation. ( 29230849 )
2017
48
Utilization of the Impella for hemodynamic support during percutaneous intervention and cardiogenic shock: an insight. ( 28862481 )
2017
49
De-escalation of support with veno-arterial extracorporeal membrane oxygenation and Impella for cardiogenic shock: reply. ( 28948707 )
2017
50
Bridge to transplant or recovery in cardiogenic shock in a developing country. ( 28084085 )
2017
Sources

Variations for Cardiogenic Shock

About this section
Sources

Expression for Cardiogenic Shock

About this section
Search GEO for disease gene expression data for Cardiogenic Shock.
Sources

Pathways for Cardiogenic Shock

About this section

Pathways related to Cardiogenic Shock according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Folate Metabolism 1
Show member pathways
 11.46 CRP IL6 PLAT
2
IL6-mediated signaling events 1
Show member pathways
 11.19 CRP IL6
3
amb2 Integrin signaling 1
10.84 IL6 PLAT
4
Overview of nanoparticle effects 1
9.9 CRP IL6
Sources

GO Terms for Cardiogenic Shock

About this section

Biological processes related to Cardiogenic Shock according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 defense response to Gram-positive bacterium GO:0050830 9.26 CRP IL6
2 acute-phase response GO:0006953 9.16 CRP IL6
3 platelet-derived growth factor receptor signaling pathway GO:0048008 8.96 PIK3C2A PLAT
4 negative regulation of lipid storage GO:0010888 8.62 CRP IL6
Sources

Sources for Cardiogenic Shock

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....